Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Language
Publication year range
1.
J Neuroimmunol ; 395: 578430, 2024 Oct 15.
Article in English | MEDLINE | ID: mdl-39128431

ABSTRACT

New-onset refractory status epilepticus (NORSE) is a devastating clinical condition that often leads to severe disability. Intrathecal dexamethasone (IT-DEX) has been reported to improve refractory status epilepticus. We present an 11-year-old female with anti-GAD 65 encephalitis presenting as NORSE who had minimal response to standard anti-seizure medications and first-line immunotherapies. The patient received 6 doses of IT-DEX in conjunction with rituximab which correlated with subsequent decreased neuroinflammation, reduced seizure burden and aided in weaning anesthetic infusions. Our case with literature review suggests IT-DEX may be utilized as an early intervention in those with refractory status epilepticus from various etiologies.


Subject(s)
B-Lymphocytes , Dexamethasone , Encephalitis , Status Epilepticus , Humans , Female , Child , Encephalitis/immunology , Encephalitis/drug therapy , Dexamethasone/therapeutic use , Dexamethasone/administration & dosage , Status Epilepticus/drug therapy , Status Epilepticus/etiology , Status Epilepticus/immunology , B-Lymphocytes/immunology , Glutamate Decarboxylase/immunology , Rituximab/therapeutic use , Injections, Spinal , Hashimoto Disease/drug therapy , Hashimoto Disease/diagnosis , Hashimoto Disease/immunology , Lymphocyte Depletion/methods , Autoantibodies/blood
SELECTION OF CITATIONS
SEARCH DETAIL